GlassScriptPhysician profile
Mary Oaks
NPI 1588143150
$2,128.07
in general payments reported to CMS, 2019-2025
27 companies · $676 in 2025
The $676 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $288 · 2023: $274 · 2024: $530 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.43 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $589.59 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $363.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $155.54 | 2022-2025 | |
| Amgen INC. | $153.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $105.21 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $80.99 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $70.80 | 2021-2024 | Airsupra |
| Gilead Sciences, INC. | $68.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.84 | 2021-2023 | Ofev |
| Abbvie INC. | $53.75 | 2021-2023 | |
| Welch Allyn | $44.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $43.21 | 2024-2025 | Voquezna |
| Pfizer INC. | $35.35 | 2023-2024 | |
| Atricure, INC. | $31.92 | 2024 | |
| Merck Sharp & Dohme LLC | $31.54 | 2021-2023 | Vaxelis, Gardasil 9, M-M-R II |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $30.25 | 2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $29.51 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2022 | |
| Axsome Therapeutics, INC. | $22.84 | 2025 | Symbravo |
| Dexcom, INC. | $21.63 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.31 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $19.40 | 2022 | |
| Esperion Therapeutics, INC. | $16.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.15 | 2022 | |
| Bausch Health US, LLC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Oaks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.